Trial Profile
A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg in the Morning vs Lapaquistat Acetate 100 mg in the Evening vs Lapaquistat Acetate 50 mg Twice Daily vs Placebo in Subjects With Hypercholesterolemia.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapaquistat (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 25 Mar 2009 New trial record